title: Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders.
abstract: Combinations of HLA and killer immunoglobulin-like receptors (KIR) may affect outcome in T-cell depleted haematopoietic stem cell transplantation (HSCT). The KIR gene family includes inhibitory (KIR2DL and 3DL) and activating receptors (KIR2DS). Ligands are HLA-C (KIR2D) and HLA-Bw4 (KIR3DL1) for inhibitory KIR and are still unknown for activating KIR. The impact of activating KIR genotypes from donor and recipient is poorly documented in HSCT outcome. Here, HLA and KIR genotypes were determined in 131 pairs from non-T-cell depleted HLA-identical sibling HSCT. No effect of 'missing KIR ligand' was detected on acute graft-versus-host disease (GVHD), relapse, survival or infections even in myeloid malignancies. However, additional activating KIR genes in the donor compared to the recipient's genotype or an identity between donor and recipient activating KIR genotypes was associated with a lower transplant-related mortality (TRM) (P=0.005) and in a multivariate analysis with a better survival (P=0.02, HR=0.28; P=0.013, HR=0.29) and a lower incidence of cytomegalovirus (CMV) reactivation (P=0.009, HR=0.36). These data highlight the impact of donor-activating KIR genes on TRM, overall survival and CMV reactivation in HLA-identical sibling HSCT.
authors.affiliation: Laboratoire d'Immunologie et d'Histocompatibilité, Hôpital Saint-Louis, CIB-HOG, AP-HP, Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Chen
authors.forename: M
authors.initials: M
authors.lastname: Busson
authors.forename: V
authors.initials: V
authors.lastname: Rocha
authors.forename: M-L
authors.initials: ML
authors.lastname: Appert
authors.forename: V
authors.initials: V
authors.lastname: Lepage
authors.forename: N
authors.initials: N
authors.lastname: Dulphy
authors.forename: P
authors.initials: P
authors.lastname: Haas
authors.forename: G
authors.initials: G
authors.lastname: Socié
authors.forename: A
authors.initials: A
authors.lastname: Toubert
authors.forename: D
authors.initials: D
authors.lastname: Charron
authors.forename: P
authors.initials: P
authors.lastname: Loiseau
mesh_terms: D000293:Adolescent; D000328:Adult; D001782:Blood Donors; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000401:mortality; D002648:Child; D002675:Child, Preschool; D003587:Cytomegalovirus / Q000235:genetics; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000235:genetics* / Q000401:mortality; D018572:Disease-Free Survival; D005260:Female; D005838:Genotype; D006680:HLA Antigens; D006801:Humans; D008212:Lymphocyte Depletion; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications / Q000235:genetics* / Q000401:mortality / Q000628:therapy / Q000821:virology; D011971:Receptors, Immunologic / Q000235:genetics*; D054340:Receptors, KIR; D054341:Receptors, KIR3DL1; D012189:Retrospective Studies; D035781:Siblings; D015996:Survival Rate; D013601:T-Lymphocytes; D014184:Transplantation, Homologous; D014775:Virus Activation / Q000235:genetics*
chemical_list: D006680:HLA Antigens; C515083:KIR3DL1 protein, human; D011971:Receptors, Immunologic; D054340:Receptors, KIR; D054341:Receptors, KIR3DL1